Shanghai Shen Lian Biomedical Corp
SSE:688098
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Yamashin Filter Corp
TSE:6240
|
JP |
|
Chongqing QinAn M&E PLC
SSE:603758
|
CN |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shanghai Shen Lian Biomedical Corp
SSE:688098
|
3.7B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
Shanghai Shen Lian Biomedical Corp
Glance View
Shanghai Shen Lian Biomedical Corp. engages in the research, development, and manufacture of vaccines for the animal farming industry. The company is headquartered in Shanghai, Shanghai and currently employs 297 full-time employees. The company went IPO on 2019-10-28. The firm is committed to the research & development of foot and mouth disease vaccines, which are used to protect animals from foot and mouth diseases. The firm's main product are swine foot and mouth disease vaccines, and it also provides cattle foot and mouth disease vaccines, other swine vaccines, and other veterinary diagnostic reagents. The firm mainly sells its products within domestic market.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Shanghai Shen Lian Biomedical Corp is 58.2%, which is below its 3-year median of 65.8%.
Over the last 3 years, Shanghai Shen Lian Biomedical Corp’s Gross Margin has decreased from 72.5% to 58.2%. During this period, it reached a low of 58.2% on May 1, 2025 and a high of 75.2% on Dec 31, 2022.
